

Ryah Medtech Inc

12:15 27 Jun 2019

RYAH Medtech takes aim at the CSE with reverse takeover of Prime Blockchain

RYAH Medtech Inc, the company behind the first dose-measuring vaporizer, is making a strong play for the Canadian Security Exchange by moving forward with a reverse takeover of Prime Blockchain.

The privately held companies signed a binding letter of intent under which Prime Blockchain will acquire any outstanding securities of RYAH's parent company.

The Quebec company will be required to change its name and replace its directors with nominees from RYAH.

READ: RYAH Medtech wins CE mark for RYAH vaporizer and sets sights on European market

Prime Blockchain is a company in good standing with the CSE, RYAH CEO Greg Wagner told Proactive, and one that the exchange has already done due diligence on. That makes it easier for the combined company to go public.

"This new letter of intent was executed for the purpose of accelerating our listing plans on the CSE and further reflects our commitment to provide liquidity, transparency and new opportunities to strategic partners, future investors and current investors alike," Wagner said.

RYAH Medtech is a New York-based company that brings big data to dry herb medicine. Its signature vaporizer can precisely track dose and temperature and pairs with an app that uses artificial intelligence to help patients identify what treatments work best for them.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter [@andrew_kessel](https://twitter.com/andrew_kessel)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

Share Information

Code: RYAH
Listing: PRIVATE-NA
Sector: Cannabis
Website: us.ryah.com

Company Synopsis:

*RYAH is the first vaporizer that lets users track and control how much they inhale, ensuring consistent, predictable results. It offers accurate temperature and dosing control down to the millileter. *

*The device tracks the effects of each session and uses artificial intelligence to help select the best strain of cannabis for any patient's symptoms. *

action@proactiveinvestors.com

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Ryah Medtech Inc named herein, including the promotion by the Company of Ryah Medtech Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).